复星医药重酒石酸去甲肾上腺素注射液获注册批准

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical Co., has received approval from the National Medical Products Administration for the registration of a drug, which is indicated for the treatment of acute hypotensive states and as an auxiliary treatment for cardiac arrest [1] Group 1 - The approved drug is a formulation of dexmedetomidine hydrochloride injection [1] - The indications for the drug include restoring blood pressure in acute hypotensive states, assisting in cardiac arrest treatment, and maintaining blood pressure post-cardiac arrest [1] - The drug is also indicated as an auxiliary treatment for shock due to insufficient blood volume, aimed at temporarily maintaining cerebral and coronary perfusion until volume resuscitation takes effect [1]